Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP

BACKGROUND: Patients with carcinoma of unknown primary (CUP) have a dismal prognosis, even when treated with multi-agent chemotherapy. We hypothesised that adding the epidermal growth-factor receptor (EGFR) inhibitor cetuximab to standard first-line chemotherapy with paclitaxel and carboplatin would...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Folprecht, Gunnar, Trautmann, Karolin, Stein, Alexander, Huebner, Gerdt, Stahl, Michael, Kasper, Stefan, Kretzschmar, Albrecht, Köhne, Claus-Henning, Grünwald, Viktor, Hofheinz, Ralf-Dieter, Schütte, Katharina, Löffler, Harald, Bokemeyer, Carsten, Krämer, Alwin
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7884392/
https://ncbi.nlm.nih.gov/pubmed/33235314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01141-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados